Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT)  Yago Nieto, MD, PhD, Roland Bassett, MS, Chitra Hosing, MD, Roy B. Jones, MD, PhD, Ben C. Valdez, PhD, Ashley Kingham, PA, Sairah Ahmed, MD, Amin M. Alousi, MD, Paolo Anderlini, MD, Uday R. Popat, MD, Muzaffar H. Qazilbash, MD, Elizabeth J. Shpall, MD, Partow Kebriaei, MD, Jonathan E. Brammer, MD, Yasuhiro Oki, MD, Michelle A. Fanale, MD, Farzaneh Maadani, BS, Gabriela Rondon, MD, Richard E. Champlin, MD, Borje S. Andersson, MD, PhD  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S227-S228 (March 2016) DOI: 10.1016/j.bbmt.2015.11.634 Copyright © 2016 Terms and Conditions

Figure 1 Outcomes of the R/R subgroups treated with Gem/Bu/Mel and BEAM. Fig. 1A: EFS. Fig 1B: OS Biology of Blood and Marrow Transplantation 2016 22, S227-S228DOI: (10.1016/j.bbmt.2015.11.634) Copyright © 2016 Terms and Conditions